Abstract:
:Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 10(9)/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 × 10(9)/L. Eighty-nine patients with GF were reported, and 80 patients received a second SCT. The 5-year survival probability was 31% (95% confidence interval [CI]: 18-44%), and the incidences of non-relapse mortality and relapse estimated by competing risks were 47% (95% CI: 36-58%) and 21% (95% CI: 4-28%). The strategy adopted to treat GF was heterogeneous, and no approach could be unequivocally recommended for this situation. The prognosis of patients with GF was poor even after successful recovery from GF.
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Ferrà C,Sanz J,Díaz-Pérez MA,Morgades M,Gayoso J,Cabrera JR,Villaescusa T,Sampol MA,Fernández-Avilés F,Solano C,Ortín M,Duarte R,Cuesta M,Heras I,de la Serna J,Moraleda JM,Barrenetxea C,González-Vicent M,Sanz G,Ribedoi
10.3109/10428194.2014.930849subject
Has Abstractpub_date
2015-03-01 00:00:00pages
656-62issue
3eissn
1042-8194issn
1029-2403journal_volume
56pub_type
杂志文章,多中心研究abstract::Allogeneic stem-cell transplantation (SCT) is potentially curative treatment for AML and MDS. New conditioning regimens are continuously explored trying to reduce toxicity while maintaining antileukemia effect. Treosulfan is an alkylating agent with in vitro cytotoxicity against leukemia as well as myeloablative and i...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190701671051
更新日期:2007-12-01 00:00:00
abstract::The aim of this study was to assess life goal achievements in long-term survivors (LTS) receiving cranial radiotherapy (CRT) as central nervous system (CNS) prophylaxis for acute lymphoblastic leukemia (ALL) during childhood, compared to healthy individuals. Participants in this study were 141 LTS treated in our cente...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2012.710903
更新日期:2013-02-01 00:00:00
abstract::A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the to...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.1080/10428190290021339
更新日期:2002-05-01 00:00:00
abstract::B-cell chronic lymphocytic leukemia (CLL) is characterized by profound immune dysfunction and a marked resistance to apoptosis. Understanding the cellular biology of immune effector cells from CLL patients as well as leukemic target cells is essential to developing immune mediated therapeutic strategies for CLL. In th...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190009113387
更新日期:2000-11-01 00:00:00
abstract::Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199909093744
更新日期:1999-03-01 00:00:00
abstract::The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2011.603444
更新日期:2012-01-01 00:00:00
abstract::During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with re...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428190109060343
更新日期:2001-05-01 00:00:00
abstract::The incidence of documented infections after autologous peripheral blood progenitor cells transplantation (PBPCT) was retrospectively evaluated in 86 consecutive patients (47 males 39 females; median age 36 years, range, 18-63) treated in our institution; 83 patients had refractory hematological malignancies (40 non-H...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199809050943
更新日期:1998-06-01 00:00:00
abstract::The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2018.1466294
更新日期:2019-01-01 00:00:00
abstract::Myocyte enhancer factor 2C (MEF2C) encodes a transcription factor which is ectopically expressed in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, deregulated directly by ectopically expressed homeodomain protein NKX2-5 or by loss of promoter regions via del(5)(q14). Here, we analyzed the MEF2C 5'-region, thu...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2010.537003
更新日期:2011-02-01 00:00:00
abstract::A 31-year-old woman with acute myeloblastic leukemia (AML) underwent allogeneic peripheral blood stem cell transplant (PBSCT). On day +274 following transplantation, the patient had severe chest pain, high-grade fever, and general fatigue. Electrocardiographic examination revealed ST segment elevation, and echocardiog...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190310001597973
更新日期:2004-02-01 00:00:00
abstract::The long-term results of postremission chemotherapy for 122 consecutive, unselected adults (15-65 years) with acute myeloid leukemia (AML) were assessed in two sequential prospective studies involving an identical 3/7-type induction regimen, and in those achieving remission, another course for early consolidation usin...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3109/10428199409051684
更新日期:1994-09-01 00:00:00
abstract:UNLABELLED:We retrospectively analyzed the incidence of thrombotic and infectious complications in relation with the use of central venous catheters (CVCs), in a series of patients with hematological malignancies and low platelet and leucocyte counts. PATIENTS AND METHODS:126 patients with hematological malignancies w...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190309178770
更新日期:2003-09-01 00:00:00
abstract::We present a female patient with monoclonal gammopathy of undetermined significance who has remained stable for five years but evolved to overt myeloma in strict temporal relationship with the diagnosis of GH-secreting pituitary macroadenoma. IGF-I serum levels correlated with serum and urine M component. Since the in...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819021000037895
更新日期:2003-03-01 00:00:00
abstract::We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep immunoparesis was defined that one of uninvolved immunoglobulins was below 50% the lower limit of normal ranges, partial immunoparesis was defi...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2020.1855345
更新日期:2020-12-04 00:00:00
abstract::The epitope in the frame region (FR) of the immunoglobulin heavy chain variable region (IgHV) is a potential target for lymphoma immunotherapy. Our previous work identified a FR-derived nonapeptide (QLVQSGAEV) capable of in vitro eliciting anti-lymphoma specific cytotoxic T lymphocytes (CTLs) in lymphocytes from human...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2011.577257
更新日期:2011-09-01 00:00:00
abstract::Central to discovering novel approaches to treating leukemias and lymphomas is a clear understanding of the signaling networks which lead to unchecked cell cycle progression, proliferation, and survival. Cyclic-adenosine monophosphate (cAMP) responsive element-binding protein (CREB) represents a critical integrator of...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428194.2011.584994
更新日期:2011-11-01 00:00:00
abstract::The transduction of exogenous hepatocyte growth factor (HGF) genes to spleen T lymphocytes and the immune effects of syngeneic spleen graft on spleen lymphoma cells were studied in LEW/Sea rats. Three different systems were designed. (1) Six female rats and six male rats received irradiated spleen graft and were follo...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819031000057360
更新日期:2003-01-01 00:00:00
abstract::Acute myeloid leukemia (AML) is infrequent in patients with human immunodeficiency virus (HIV) infection. Among AML, acute promyelocytic leukemia (APL) has been rarely described in such patients, with only one case being published. We report a 30 years-old intravenous drug abuser HIV-infected male with APL who attaine...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199709050899
更新日期:1997-08-01 00:00:00
abstract::Blastic Natural Killer (NK)-cell lymphoma is a relatively new entity which has been recently included in the WHO classification. CD4 expression is observed in most cases of blastic NK-cell lymphomas and has been related with skin tropism. We report an unusual CD4 negative blastic NK-cell lymphoma with primary presenta...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190410001723232
更新日期:2004-10-01 00:00:00
abstract::Arsenic trioxide (As2O3) is currently employed as a treatment for relapsed acute promyelocytic leukemia (APL), where it can induce remission in greater than 90% of patients, but is ineffective in patients with non-APL acute myeloid leukemia (AML). As2O3 induces apoptosis in APL cells through mechanisms dependent and i...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190802353617
更新日期:2008-10-01 00:00:00
abstract::Peripheral lymphopenia is a well-known negative prognostic marker in classical Hodgkin lymphoma (cHL). We characterized the peripheral B-cell compartment in a prospective cohort of 83 pediatric cHL patients. We observed significantly low total B-cell counts (<100 cells/µl) in 31 of 83 patients (37%). More specifically...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2020.1834090
更新日期:2020-10-23 00:00:00
abstract::We describe a patient with primary anaplastic large cell lymphoma of the forearm presenting with compartment syndrome. Urgent decompression fasciotomy and combination chemotherapy resulted in durable remission status. This is followed by a review of primary skeletal muscle lymphoma in the English literature. ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199909058467
更新日期:1999-05-01 00:00:00
abstract::A novel cultured cell line, NCU-L-1, was established from a 71-year-old Japanese woman with acute lymphoblastic leukemia, L3 FAB, Burkitt's type. The NCU-L-1 cells were shown to have a mature B-cell phenotype on the basis of immunologic surface marker analysis; including IgG Lambda surface immunoglobulins, CD19, CD20 ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199009050977
更新日期:1990-01-01 00:00:00
abstract::It is unknown whether rituximab increases the risk of second primary malignancies (SPMs) in patients with diffuse large cell B-cell lymphoma (DLBCL). We assessed SPMs in DLBCL patients diagnosed between 1996 and 2014 in comparison with the general Israeli population and dependent on rituximab treatment. Jewish patient...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2020.1779257
更新日期:2020-11-01 00:00:00
abstract::Richter's transformation (RT) refers to the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL). Approximately, 2-10% of patients with CLL develop RT, most often as diffuse large B-cell lymphoma. To assess the incidence of RT, we examined risk factors for RT and death among patien...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2020.1719092
更新日期:2020-06-01 00:00:00
abstract::EBER in situ hybridization (EBER) and LMP-1 immunohistochemistry (LMP-1) are widely used for identifying Epstein-Barr virus (EBV) within tumor cells of Hodgkin lymphoma (HL), but measurement error has never been formally evaluated. To determine assay reliability, 40 HL tumors with known EBV status were stained for bot...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819032000141310
更新日期:2004-03-01 00:00:00
abstract::Analysis of different ribonucleotide reductase inhibitors to modulate arabinosylcytosine (ara-C) metabolism suggested that pretreatment with arabinosyl-2-fluoroadenine (F-ara-A) significantly potentiated the rate of ara-CTP (5'-triphosphate of ara-C) accumulation in both quiescent lymphocytes (p = 0.046) and in cyclin...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199309149122
更新日期:1993-01-01 00:00:00
abstract::The decision to operate on hematology patients with abdominal emergencies can be difficult, as neutropenia and thrombocytopenia are common and the usual causes of abdominal pain are broad. We conducted a retrospective observational study including all hematology patients undergoing emergency abdominal surgery between ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2017.1296145
更新日期:2017-10-01 00:00:00
abstract::We investigated whether etoposide might be a suitable alternative to anthracyclins for the treatment of elderly patients with acute myeloid leukemia (AML) in whom anthracyclins are contraindicated. In total, 88 patients over 60 years old were treated in our department between 1988 and 2000 for de novo or secondary AML...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190400013134
更新日期:2005-03-01 00:00:00